Get the Stockscreener App
1,022.85
1.21%
13.47
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,022.85, with a volume of 1.80M.
It is up +1.21% in the last 24 hours and up +0.38% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,009.38
Open:
$1008.76
24h Volume:
1.80M
Relative Volume:
0.48
Market Cap:
$914.57B
Revenue:
$59.42B
Net Income/Loss:
$18.41B
P/E Ratio:
50.59
EPS:
20.2197
Net Cash Flow:
$6.44B
1W Performance:
+1.12%
1M Performance:
+0.38%
6M Performance:
+25.81%
1Y Performance:
+30.58%
1-Day Range:
$1,003.50
$1,028.90
1-Week Range:
$977.12
$1,031.56
52-Week Range:
$623.78
$1,111.99
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,021.84 | 903.41B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
210.68 | 505.98B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
221.36 | 395.86B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
132.16 | 253.97B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
99.54 | 245.75B | 63.90B | 19.05B | 13.05B | 7.5596 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Eli Lilly to Build $6-Billion Alabama Facility - AdvancedManufacturing.org
Moody’s affirms Eli Lilly’s Aa3 rating, outlook revised to positive By Investing.com - Investing.com Canada
Eli Lilly (LLY) Reports Promising Results from Phase 3 EMBER-3 S - GuruFocus
Eli Lilly announces updated results from Phase 3 EMBER-3 study of Inluriyo - TipRanks
Exclusive: FDA leaders pushed to cut Lilly weight-loss pill review time - Reuters
Lilly shifts ambition for broader oral SERD label to largest oncology trial in company history - Fierce Pharma
Eli Lilly's Next-Generation Obesity Drug Secures First Phase III Win - TradingView
Eli Lilly touts strong results of new experimental weight loss drug retatrutide - Straight Arrow News
Eli Lilly Unveils New Data Showing Longer Survival With Breast Cancer Drug In Late-Stage Study - Stocktwits
U.S. Regulators Pushed to Fast-Track Approval of Eli Lilly’s Weight-Loss Pill: Reports - TipRanks
Eli Lilly (LLY) Gains EU Support for Mounjaro Use in Younger Pat - GuruFocus
EU committee backs extending use of Lilly's diabetes drug for children aged 10 and above - Reuters
Lilly's next-gen drug shows greater weight loss than Zepbound in late-stage trial - Reuters
Truist Securities reiterates Buy rating on Eli Lilly stock at $1,182 - Investing.com
Lilly to Invest $6B in New API Manufacturing Facility in Alabama - Contract Pharma
Eli Lilly Stock (NYSE: LLY) in Focus: Retatrutide’s Near-30% Weight-Loss Data, FDA Fast-Track Questions for Orforglipron, and Fresh Analyst Forecasts (Dec. 12, 2025) - ts2.tech
US FDA likely to speed up evaluation of Eli Lilly's weight loss pill - medwatch.com
Eli Lilly (LLY) Boosts Dividend by 15.3% - GuruFocus
FDA May Fast-Track Eli Lilly’s Weight Loss PillEli Lilly (NYSE:LLY) - Benzinga
Eli Lilly & Co: Promising Future with Strong TRIUMPH-4 Trial Results and Strategic Pipeline Driving Growth - TipRanks
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (Dec 2025) - 24/7 Wall St.
Eli Lilly (LLY) Pushes for Faster FDA Review of Weight Loss Pill - GuruFocus
Think Eli Lilly is expensive? This metric says otherwise. - MSN
Top FDA brass pushes for a faster review of Lilly’s obesity pill - Seeking Alpha
Think Eli Lilly Is Expensive? This Metric Says Otherwise. - The Motley Fool
Exclusive-US FDA brass pushed internally for speedier Lilly weight-loss pill verdict - Yahoo
Lilly CEO talks innovation, ‘generational impact’ ahead of 150th anniversary - Inside INdiana Business
Eli Lilly to build $6 B worth API manufacturing facility in US - BioSpectrum Asia
A Decade of Rewards: $47 Bil From Eli Lilly Stock - Trefis
Lilly’s next-gen drug tops Zepbound on weight loss in late-stage trial - WHTC
Eli Lilly's Retatrutide Shows 28.7% Weight Loss in Phase 3 Trial - 조선일보
Oh no, Ozempic! Eli Lilly’s New Weight-Loss Drug KOs Rival Treatments - The Daily Upside
Eli Lilly Drug for 3 Obesity Targets Sets New High Bar for Weight Loss in a Clinical Trial - MedCity News
Pharmaceutical giant Lilly plans $6 billion advanced manufacturing plant in Huntsville, Alabama - Alabama Weather Network
Eli Lilly's $6B boost: New jobs, growth for Huntsville-Limestone County area - WAAY 31 News
Lilly’s Retatrutide Raises Weight-Loss Bar In First Phase III Readout - Citeline News & Insights
Eli Lilly's $6 billion boost means new jobs, growth for Huntsville-Limestone County area - WAAY 31 News
Eli Lilly's $6B boost: new jobs, growth for Limestone County - WAAY 31 News
Eli Lilly's next-gen obesity drug shows biggest weight loss yet in clinical trial - AOL.com
Eli Lilly (LLY) Stock After Hours on December 11, 2025: Retatrutide Breakthrough, $6B Plant — and What to Watch Before Friday’s Open - ts2.tech
Eli Lilly Puts Obesity Field 'On Notice' With Best Weight Loss - Investor's Business Daily
Stock Movers: Mosaic Company, Eli Lilly, Lululemon - Bloomberg.com
New Eli Lilly Drug Retatrutide Brought Major Weight Loss in Trial - The New York Times
S&P 500 Slips as Oracle’s AI Capex Shock Knocks Wind Out of Post-Fed Rally - Investing.com
Eli Lilly Reveals $6B Pharmaceutical Facility in Alabama - Thomasnet
Stock Movers: Eli Lilly, Gemini Space Station, Oracle - Bloomberg.com
Eli Lilly Says Trial of Weight-Loss Drug Retatrutide Yields Encouraging Results - marketscreener.com
Eli Lilly's (LLY) Retatrutide Surpasses Expectations in Weight L - GuruFocus
Premarket Movers Thursday Oracle Stock Drops Eli Lilly Surges Amazon Under Pressure - TECHi
Market Voices: Lilly's new obesity drug, Bessent, EQT's robotics move - Seeking Alpha
Eli Lilly’s Adverum Acquisition: What They Didn’t Say in the Press Release! - Smartkarma
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.37%
1.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):